Total Payments
$505,158
2024 Payments
$66,245
Companies
18
Transactions
217
Medicare Patients
1,159
Medicare Billing
$162,190
Payment Breakdown by Category
Consulting$287,990 (57.0%)
Research$182,407 (36.1%)
Travel$19,542 (3.9%)
Other$11,060 (2.2%)
Food & Beverage$4,151 (0.8%)
Education$9.09 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $287,990 | 96 | 57.0% |
| Unspecified | $182,407 | 17 | 36.1% |
| Travel and Lodging | $19,542 | 49 | 3.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,060 | 4 | 2.2% |
| Food and Beverage | $4,151 | 50 | 0.8% |
| Education | $9.09 | 1 | 0.0% |
Payments by Type
General
$322,751
200 transactions
Research
$182,407
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $163,100 | 15 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $102,060 | 40 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $89,501 | 62 | $0 (2024) |
| Millennium Pharmaceuticals, Inc. | $43,060 | 12 | $0 (2017) |
| GENZYME CORPORATION | $37,786 | 14 | $0 (2024) |
| Janssen Biotech, Inc. | $29,139 | 31 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $9,880 | 15 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $6,343 | 4 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $4,894 | 5 | $0 (2024) |
| Legend Biotech USA Inc. | $3,830 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,245 | 40 | Alexion Pharmaceuticals, Inc. ($30,820) |
| 2023 | $119,260 | 57 | NOVARTIS PHARMACEUTICALS CORPORATION ($64,184) |
| 2022 | $37,754 | 28 | GENZYME CORPORATION ($11,202) |
| 2021 | $26,326 | 12 | GENZYME CORPORATION ($9,477) |
| 2020 | $93,617 | 14 | Takeda Pharmaceuticals U.S.A., Inc. ($74,950) |
| 2019 | $100,054 | 30 | Takeda Pharmaceuticals U.S.A., Inc. ($85,950) |
| 2018 | $7,895 | 11 | Rigel Pharmaceuticals, Inc. ($4,557) |
| 2017 | $54,007 | 25 | Millennium Pharmaceuticals, Inc. ($43,060) |
All Payment Transactions
217 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | VEOPOZ (Biological) | Consulting Fee | Cash or cash equivalent | $1,854.00 | General |
| Category: RARE DISEASES | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $625.51 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Scientific Affairs, LLC | — | Food and Beverage | In-kind items and services | $146.88 | General |
| 11/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $225.00 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Rare Disease | ||||||
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,920.00 | General |
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $70.65 | General |
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $52.39 | General |
| 09/27/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $48.74 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $646.95 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $453.00 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $448.00 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $438.00 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $68.00 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $34.12 | General |
| 09/26/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/12/2024 | Janssen Scientific Affairs, LLC | TECVAYLI (Biological) | Consulting Fee | Cash or cash equivalent | $1,907.50 | General |
| Category: Oncology | ||||||
| 08/12/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $5,115.74 | Research |
| Study: HEOR | ||||||
| 06/28/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $1,856.25 | General |
| Category: Immunology | ||||||
| 06/24/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 06/12/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,220.00 | General |
| 06/01/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | — | Cash or cash equivalent | $972.27 | Research |
| Study: HEOR • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS PLACEBO PLUS LENALIDOMIDE AND DEXAMETHASONE IN ADULT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $74,950 | 1 |
| A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation SCT | Takeda Pharmaceuticals U.S.A., Inc. | $64,200 | 9 |
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $20,650 | 3 |
| LIK-MS -111563 Paroxysmal Nocturnal Hemoglobinuria: Review of the Patient Experience and Treatment Landscape | Novartis Pharmaceuticals Corporation | $15,419 | 1 |
| HEOR | Novartis Pharmaceuticals Corporation | $6,088 | 2 |
| C16029 North America Investigator Meeting - PM Break 7-13 | Takeda Pharmaceuticals U.S.A., Inc. | $1,100 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 279 | 473 | $137,223 | $40,667 |
| 2022 | 7 | 342 | 560 | $165,084 | $49,686 |
| 2021 | 7 | 291 | 504 | $56,026 | $41,652 |
| 2020 | 7 | 247 | 395 | $42,923 | $30,185 |
Total Patients
1,159
Total Services
1,932
Medicare Billing
$162,190
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 163 | 272 | $78,062 | $25,259 | 32.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 97 | $26,869 | $5,990 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $13,266 | $3,716 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 16 | $7,120 | $2,270 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 24 | $4,536 | $1,485 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 16 | $4,640 | $1,219 | 26.3% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Office | 2023 | 25 | 26 | $2,730 | $727.48 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 198 | 345 | $99,889 | $32,922 | 33.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 83 | $22,244 | $4,645 | 20.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $14,472 | $4,126 | 28.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $11,900 | $3,055 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 41 | $7,749 | $2,354 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 13 | $5,785 | $1,789 | 30.9% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Office | 2022 | 28 | 29 | $3,045 | $795.12 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 159 | 287 | $37,845 | $27,907 | 73.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 83 | $5,800 | $4,709 | 81.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 39 | 45 | $4,576 | $3,043 | 66.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $2,816 | $2,287 | 81.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $3,226 | $2,276 | 70.6% |
| 99451 | Telephone or internet assessment and management service provided by consultative physician with written report, 5 minutes or more of medical consultative discussion and review | Office | 2021 | 33 | 33 | $1,165 | $831.14 | 71.4% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 17 | 26 | $598.52 | $598.28 | 100.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 133 | 237 | $27,056 | $18,705 | 69.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 22 | 22 | $4,899 | $3,328 | 67.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 16 | 47 | $3,675 | $2,968 | 80.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 15 | $2,453 | $1,649 | 67.2% |
About Dr. David Dingli, M.D
Dr. David Dingli, M.D is a Hematology & Oncology healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891769766.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Dingli, M.D has received a total of $505,158 in payments from pharmaceutical and medical device companies, with $66,245 received in 2024. These payments were reported across 217 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($287,990).
As a Medicare-enrolled provider, Dingli has provided services to 1,159 Medicare beneficiaries, totaling 1,932 services with total Medicare billing of $162,190. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Rochester, MN
- Active Since 02/15/2006
- Last Updated 08/13/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891769766
Products in Payments
- Ninlaro (Drug) $85,950
- NINLARO (Drug) $43,060
- ULTOMIRIS (Biological) $24,055
- DARZALEX (Biological) $15,541
- Fabhalta (Drug) $15,270
- SOLIRIS (Drug) $12,039
- SARCLISA (Biological) $8,773
- EMPAVELI (Drug) $6,322
- Tavalisse (Drug) $6,280
- Ultomiris (Drug) $5,550
- ENJAYMO (Biological) $4,571
- SOLIRIS (Biological) $3,900
- CARVYKTI (Biological) $3,830
- TECVAYLI (Biological) $3,473
- VEOPOZ (Biological) $1,854
- VYVGART (Drug) $1,400
- CARVYKTI (Drug) $1,000
- ELREXFIO (Drug) $150.00
- Empaveli (Drug) $21.33
- ABECMA (Biological) $9.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028
Dr. Alok Khorana, M.d, M.D
Hematology & Oncology — Payments: $205,803
Hematology & Oncology $205,803